Latest Conference Coverage

Bart P. Leroy, MD, PhD, head, Department of Ophthalmology, Center for Medical Genetics, Ghent University Hospital, discussed the ongoing efforts to verify the efficacy of Spark Therapeutics’ Luxturna.

The director of clinical research at Sierra Eye Associates discussed the latest results from a clinical trial evaluating 4D Molecular Therapeutics’ gene therapy, 4D-150, that were presented at ARVO’s 2023 conference.

The single-administration allogeneic cell therapy has shown positive safety—and signs of efficacy—in preliminary data from the first 2 patients dosed with the Neurona Therapeutics’ product.

Arnaud Lacoste, PhD, the chief scientific officer of Aurion Biotech, discussed AURN001, a corneal endothelial cell therapy that was recently approved in Japan, and had a nonclinical data read out at ARVO 2023.

The head of the Department of Ophthalmology at the Center for Medical Genetics at Ghent University Hospital discussed the need to reevaluate requirements for regulatory approval for ophthalmology gene therapies.

Krystal Biotech's B-VEC was well-tolerated and the treated patient experienced significant improvement in visual acuity.

The cofounder and chief scientific officer of Xcell Biosciences discussed the company’s research with a newly developed assay method that was presented at AACR’s 2023 conference.

The head of immunology at Turn Biotechnologies discussed preclinical data demonstrating proof-of-concept with the company’s epigenome reprogramming platform.

The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.

The chief medical officer of Trisalus Life Sciences discussed the company’s PEDD system and SD-101.

Updated 52-week follow-up data were presented at the EBMT meeting.

The cofounder and chief scientific officer of Xcell Biosciences discussed the limitations of the methods currently used for modeling in preclinical cell therapy research for solid tumors.

New data from imaging analyses on RG6501 were presented at the ARVO 2023 Annual Meeting.

The senior director of immunology at Arsenal Bio discussed advantages of ICTs and the company’s clinical trial in ovarian cancer.

The study found significant improvements in BCVA, in contrast to several other studies evaluating Luxturna.

The data, presented at ARVO's 2023 conference, also showed a favorable safety profile.

The vice president of business development and alliances at Prescient Therapeutics discussed the mechanism of the OmniCAR technology.

The chief scientific officer of Aurion Biotech discussed the properties of the cell therapy for corneal dystrophies, which was recently approved in Japan.

The new data builds upon positive long-term follow-up data from clinical trials.

The head of the Department of Ophthalmology at the Center for Medical Genetics, Ghent University Hospital, discussed the results of a post-marketing study presented at ARVO’s 2023 conference.

The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed early data from a phase 1 trial of the PBMC-derived therapy.

The safety profile of lenadogene nolparvovec at 5-years post treatment was similar to 2-year data.

The associate director of research at Lyell Immunopharma discussed the company’s programs and newest technologies aimed at solid tumors.

The instructor at Stanford Institutes of Medicine discussed the key takeaways of her research into the factors that affect CAR-T expansion.

No serious TEAEs have been related to ATSN-101 with data up to 6 months after treatment.

The chief scientific officer of Aurion Biotech discussed the investigational cell therapy AURN001.

STZ eyetrial’s treatment rAAV8.hPDE6A was otherwise deemed well-tolerated.